Skip to main content

Advertisement

Table 2 Adjuvant chemotherapy in relation to clinicopathological parameters

From: Prognostic and treatment predictive significance of SATB1 and SATB2 expression in pancreatic and periampullary adenocarcinoma

  Pancreatobiliary type Intestinal type
  No adjuvant or non-gemcitabine based n = 60 Gemcitabine based n = 50 p-value No adjuvant n = 47 Any adjuvant n = 18 P-value
No follow up, n 1 0 1.000 2 0 1.000
Received neoadjuvant treatment, n 0 2 0.204 0 0  
Sex    0.253    1.000
Female, n (%) 31 (61%) 20 (39%)   25 (71%) 10 (29%)  
Male, n (%) 29 (49%) 30 (51%)   22 (73%) 8 (27%)  
Age at surgery, years. M (IQR) 69 (62–73) 66 (60–70) 0.260 67 (62–72) 67 (56–71) 0.441
Tumour origin    0.002    0.316
Pancreas, n (%) 16 (35%) 30 (65%)     
Distal bile duct, n (%) 30 (67%) 15 (33%)     
Ampulla of Vater, n (%) 14 (74%) 5 (26%)   35 (69%) 16 (31%)  
Duodenum, n (%)     12 (86%) 2 (14%)  
Tumour size, mm. M (IQR) 30 (22–37) 30 (25–35) 0.702 23 (13–40) 30 (24.5-40) 0.690
Tumour grade    0.555    0.783
Well/moderate, n (%) 21 (50%) 21 (50%)   24 (75%) 8 (25%)  
Poor, n (%) 39 (57%) 29 (43%)   23 (70%) 10 (30%)  
Lymph nodes    0.531    0.013
Uninvolved (N0), n (%) 20 (61%) 13 (39%)   30 (86%) 5 (14%)  
Involved (N1-N2), n (%) 40 (52%) 37 (48%)   17 (57%) 13 (43%)  
Margins    0.452    0.230
Uninvolved, n (%) 5 (71%) 2 (29%)   11 (61%) 7 (39%)  
Involved or unknown, n (%) 55 (53%) 48 (47%)   36 (77%) 11 (23%)  
Perineural growth    0.362    0.229
No, n (%) 16 (64%) 9 (36%)   35 (78%) 10 (22%)  
Yes, n (%) 44 (52%) 41 (48%)   12 (60%) 8 (40%)  
Growth in lymph vessels    0.223    1.000
No, n (%) 16 (46%) 19 (54%)   21 (72%) 8 (28%)  
Yes, n (%) 44 (59%) 31 (41%)   26 (72%) 10 (28%)  
Growth in blood vessels    0.312    1.000
No, n (%) 37 (51%) 36 (49%)   43 (72%) 17 (28%)  
Yes, n (%) 23 (62%) 14 (38%)   4 (80%) 1 (20%)  
Growth in peripancreatic fat    0.649    0.142
No, n (%) 15 (60%) 10 (40%)   34 (79%) 9 (21%)  
Yes, n (%) 45 (53%) 40 (47%)   13 (59%) 9 (41%)  
T-stage    0.240    0.301
T1, n (%) 2 (67%) 1 (33%)   5 (100%) 0  
T2, n (%) 4 (33%) 8 (67%)   10 (83%) 2 (17%)  
T3, n (%) 42 (54%) 36 (46%)   18 (72%) 7 (28%)  
T4, n (%) 12 (71%) 5 (29%)   14 (61%) 9 (39%)  
Year of surgery. M (IQR) 2007.5 (2004–2010) 2009 (2007–2010) 0.004 2006 (2003–2009) 2009 (2006.5-2010) 0.372
  1. M, median. IQR, interquartile range. Bold text indicates significant p-values.